T-ALL/Lymphoma
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies (NCT06909474) | Chongqing Precision Biotech Co., Ltd | 2025-03-27 |
| The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors (NCT06911710) | Tianjin Medical University General Hospital | 2024-11-09 |
| CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (NCT05212584) | iCell Gene Therapeutics | 2022-07-01 |
Track T-ALL/Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.